|
KMID : 1001020200180020099
|
|
Journal of Urologic Oncology
2020 Volume.18 No. 2 p.99 ~ p.108
|
|
|
New Androgen Receptor Axis-Targeted Agents in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer: From Bench to Clinical Trials
|
|
Hong Jeong-Hee
|
|
|
Abstract
|
|
|
|
Bone metastasis is a common sign of disease progression in nonmetastatic castration-resistant prostate cancer (nmCRPC). It has been known to be associated with significant morbidity and mortality. Delaying or preventing development of distant metastasis is the ideal goal of treatment. There had been no standard treatment options available for patients with nmCRPC before 2018. Recent approval of new androgen receptor axis-targeted agents in the management of nmCRPC has led to rapid evolution and is worthy of detailed investigation.
|
|
|
KEYWORD
|
|
|
Castration-resistant prostate neoplasms, Neoplasm metastasis, Androgen receptor antagonists
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|